Fierce Pharma Asia—Otsuka's gene therapy deal; Astellas' $354M plant; Exelixis and Insilico's AI drug pact
Phase 1License out/inADCClinical ResultGene Therapy
Preview
Source: FiercePharma
Otsuka's gene therapy collab with Shape Therapeutics, Astellas' new manufacturing plant and an AI drug licensing deal between Exelixis and Insilico Medicine made our news this week.
Otsuka teamed up with Shape Therapeutics in an eye disease gene therapy deal potentially worth $1.5 billion. Astellas will build its third Irish manufacturing facility. Insilico Medicine out-licensed an AI-discovered cancer drug candidate to Exelixis. And more.
1. Otsuka's eye disease strategy takes Shape with $1.5B biobucks deal
In a deal potentially worth up to $1.5 billion, Otsuka has hired Shape Therapeutics to develop new gene therapies for serious eye diseases. Shape, a 2022 Fierce 15 winner, will apply its adeno-associated virus capsid discovery platform, while Otsuka will design the genetic payload. Shape will provide extra optimization with its transgene engineering technology as well.
2. Astellas lays out plans to build $354M manufacturing facility in Ireland
Astellas plans to invest 330 million euros ($354 million) to build a new manufacturing facility in Tralee, Ireland. Pending planning permits, construction will begin in 2024, and operation is expected to commence in 2028. The plant, Astellas’ third in Ireland, will make aseptic products including antibody drugs.
Exelixis has in-licensed a phase 1 small molecule from artificial intelligence drug discovery firm Insilico Medicine. For $80 million upfront and undisclosed milestone payments, Exelixis gains worldwide rights to a cancer candidate targeting USP1, which may have value in BCMA-mutated tumors, according to Insilico.
Eisai has established a first-of-its-kind “digital business.” Called Theoria, the platform aims to build an ecosystem for people living with dementia. Eisai, maker of Alzheimer’s disease drug Leqembi, will launch Theoria in Japan next April. The platform will tap various data and health records to help find people who may be at risk of developing dementia.
5. AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
AstraZeneca and Daiichi Sankyo have unveiled additional early-stage data for their TROP2 antibody-drug conjugate, nicknamed Dato-DXd. Results from just 14 patients in the phase 1b TROPION-Lung04 study showed that the combination of Dato-DXd and AZ’s PD-L1 inhibitor Imfinzi triggered a 50% tumor response rate. In a cohort of 13 patients who also received chemotherapy, the response rate was 77%.
6. Sandoz, nearing Novartis split, signs up to commercialize Samsung Bioepis' Stelara biosimilar
Sandoz continues to beef up its biosimilar portfolio as a separation from Novartis draws near. Sandoz signed a deal to commercialize Samsung Bioepis’ biosimilar to Johnson & Johnson’s immunology blockbuster Stelara in the U.S., Canada and several European countries. J&J has inked patent settlements with several companies to delay launches for their Stelara copycats until 2025.
Other News of Note:
7. In global access push, Orchid Pharma gains license to manufacture the antibiotic cefiderocol
9. Takeda commits $30M in 5 humanatarian programs (release)
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.